KR20260011665A - 삼환성 화합물 - Google Patents
삼환성 화합물Info
- Publication number
- KR20260011665A KR20260011665A KR1020257029722A KR20257029722A KR20260011665A KR 20260011665 A KR20260011665 A KR 20260011665A KR 1020257029722 A KR1020257029722 A KR 1020257029722A KR 20257029722 A KR20257029722 A KR 20257029722A KR 20260011665 A KR20260011665 A KR 20260011665A
- Authority
- KR
- South Korea
- Prior art keywords
- hydroxy
- cyclopenta
- oxepin
- hexahydro
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2023-038845 | 2023-03-13 | ||
| JP2023038845 | 2023-03-13 | ||
| PCT/JP2024/009559 WO2024190777A1 (ja) | 2023-03-13 | 2024-03-12 | 三環性化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260011665A true KR20260011665A (ko) | 2026-01-23 |
Family
ID=92755170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257029722A Pending KR20260011665A (ko) | 2023-03-13 | 2024-03-12 | 삼환성 화합물 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4682141A1 (https=) |
| JP (1) | JPWO2024190777A1 (https=) |
| KR (1) | KR20260011665A (https=) |
| CN (1) | CN120752225A (https=) |
| AU (1) | AU2024235437A1 (https=) |
| IL (1) | IL323168A (https=) |
| MX (1) | MX2025010791A (https=) |
| TW (1) | TW202440095A (https=) |
| WO (1) | WO2024190777A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120774781B (zh) * | 2025-09-11 | 2025-12-02 | 阜新瑞宁化工有限公司 | 一种6,6,6-三氟己烷-2-酮的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2335490C2 (ru) * | 2003-02-07 | 2008-10-10 | Оно Фармасьютикал Ко., Лтд. | Соединения карбоновой кислоты, фармацевтическая композиция на их основе, способ лечения и применение |
| CN101076531A (zh) * | 2004-10-12 | 2007-11-21 | 解码遗传学公司 | 用于阻塞性血管疾病的羧酸迫位取代的双环化合物 |
| WO2006090850A1 (ja) * | 2005-02-25 | 2006-08-31 | Ono Pharmaceutical Co., Ltd. | ベンズアミド化合物 |
| EP3237401B1 (en) * | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
-
2024
- 2024-03-12 JP JP2025506868A patent/JPWO2024190777A1/ja active Pending
- 2024-03-12 CN CN202480017192.9A patent/CN120752225A/zh active Pending
- 2024-03-12 AU AU2024235437A patent/AU2024235437A1/en active Pending
- 2024-03-12 KR KR1020257029722A patent/KR20260011665A/ko active Pending
- 2024-03-12 EP EP24770882.9A patent/EP4682141A1/en active Pending
- 2024-03-12 WO PCT/JP2024/009559 patent/WO2024190777A1/ja not_active Ceased
- 2024-03-12 TW TW113108935A patent/TW202440095A/zh unknown
-
2025
- 2025-09-04 IL IL323168A patent/IL323168A/en unknown
- 2025-09-12 MX MX2025010791A patent/MX2025010791A/es unknown
Non-Patent Citations (3)
| Title |
|---|
| 저널·오브·바이올로지컬·케미스트리(Journal of Biological Chemistry), 제282권, 제16호, 11613-11617 페이지 |
| 저널·오브·오가닉·케미스트리(Journal of Organic Chemistry), 제64권, 제17호, 6380-6386페이지 |
| 피토케미스트리(Phytochemistry), 제16권, 제4호, 494-495 페이지 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025010791A (es) | 2025-10-01 |
| IL323168A (en) | 2025-11-01 |
| WO2024190777A1 (ja) | 2024-09-19 |
| EP4682141A1 (en) | 2026-01-21 |
| AU2024235437A1 (en) | 2025-09-25 |
| CN120752225A (zh) | 2025-10-03 |
| TW202440095A (zh) | 2024-10-16 |
| JPWO2024190777A1 (https=) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6323629B1 (ja) | Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ | |
| JP6269862B2 (ja) | 三環性スピロ化合物 | |
| JP6149975B2 (ja) | 二環式化合物およびその医薬用途 | |
| JP7632523B2 (ja) | ベンゼン誘導体 | |
| JP5835236B2 (ja) | 二環式化合物およびその医薬用途 | |
| IL323168A (en) | Tricyclic compound | |
| JP6922712B2 (ja) | 医薬用途 | |
| JP7384179B2 (ja) | ベンゼン誘導体を含有する医薬組成物 | |
| JP2026053300A (ja) | 三環性化合物を含有する腎疾患の予防及び／又は治療剤 | |
| CA3285359A1 (en) | Tricyclic compound | |
| KR20260038836A (ko) | 삼환성 화합물을 함유하는 신장 질환의 예방 및/또는 치료제 | |
| WO2024190780A1 (ja) | 三環性化合物を含有する腎疾患の予防及び／又は治療剤 | |
| JP2026071419A (ja) | 三環性化合物を含有する腎疾患の予防及び／又は治療剤 | |
| TW202241398A (zh) | 含有ｅｐ２拮抗劑之醫藥組成物 | |
| JP2022101520A (ja) | Ｅｐ２アンタゴニストを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15 | Change to inventor requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R15-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16 | Change to inventor recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R16-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |